» Articles » PMID: 17761975

Prevalence, Clinical Pattern, and Outcome of CNS Involvement in Childhood and Adolescent Non-Hodgkin's Lymphoma Differ by Non-Hodgkin's Lymphoma Subtype: a Berlin-Frankfurt-Munster Group Report

Abstract

Purpose: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.

Patients And Methods: From October 1986 to December 2002, 2,381 patients (median age, 9.37 years; range, 0.2 to 23.8 years; female-to-male ratio, 1:2.7) from Germany, Austria, and Switzerland were registered. A total of 2,086 patients were eligible for the consecutive multicenter protocols NHL-Berlin-Frankfurt-Münster [BFM] -86, NHL-BFM-90, and NHL-BFM-95, and could be evaluated for outcome.

Results: CNS involvement was diagnosed in 141 (5.9%) of 2,381 patients and was associated with an advanced stage of NHL. The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001). Most CNS-positive patients with pB-LBL, T-LBL, or BL/B-ALL had meningeal disease. The probability of event-free survival (pEFS; +/- SE) at 5 years was 85% +/- 1% for the 2,086 protocol patients (median follow-up, 6.5 years; range, 0.3 to 17.7 years). For the 112 CNS-positive patients, pEFS was 64% +/- 5%, compared with 86% +/- 1% for the 1,927 CNS-negative patients (P < .001). Although CNS disease had no impact on pEFS for advanced-stage T-LBL patients, CNS-positive patients with BL/B-ALL had a worse average outcome than CNS-negative patients with stage IV BL/B-ALL (60% +/- 5% v 81% +/- 3%; P < .001). In multivariate analysis, CNS disease was the strongest predictor for relapse in BL/B-ALL patients with advanced-stage disease.

Conclusion: Six percent of childhood/adolescent NHL patients were CNS positive. However, the prevalence, pattern, and prognostic impact of CNS involvement differed among NHL subtypes.

Citing Articles

Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL.

Pabari R, McCarten K, Flerlage J, Lai H, Mauz-Korholz C, Dieckmann K Blood Adv. 2024; 8(18):4856-4865.

PMID: 39058968 PMC: 11416590. DOI: 10.1182/bloodadvances.2023012346.


Peritoneal Lymphomatosis in a Pediatric Patient: A Peruvian Case Report.

Principe-Collazos J, Ramos-Yataco A, Nombera-Aznaran N, Ramos-Orosco E, Sangster-Carrasco L Cureus. 2024; 16(6):e62750.

PMID: 39036148 PMC: 11260202. DOI: 10.7759/cureus.62750.


Mass spectrometry-based proteomics of cerebrospinal fluid in pediatric central nervous system malignancies: a systematic review with meta-analysis of individual patient data.

Mirian C, Thastrup M, Mathiasen R, Schmiegelow K, Olsen J, Ostergaard O Fluids Barriers CNS. 2024; 21(1):14.

PMID: 38350915 PMC: 10863112. DOI: 10.1186/s12987-024-00515-x.


B-cell precursor leukemias with -rearrangement come into the limelight.

Borkhardt A, Henze G Haematologica. 2022; 108(3):659-660.

PMID: 35484663 PMC: 9973467. DOI: 10.3324/haematol.2022.281112.


Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Guan J, Sun F, Wang J, Huang J, Lu S, Zhu J Ann Hematol. 2022; 101(4):763-771.

PMID: 34997277 DOI: 10.1007/s00277-022-04754-6.